Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1987 13
1988 7
1989 9
1990 8
1991 7
1992 6
1993 10
1994 15
1995 5
1996 2
1997 4
1998 4
1999 2
2000 2
2001 5
2002 7
2003 10
2004 3
2005 4
2006 1
2007 2
2008 3
2009 2
2010 1
2011 1
2012 1
2013 1
2015 1
2019 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

139 results
Results by year
Filters applied: . Clear all
Page 1
Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects.
Nakada T, Kudo T, Kume T, Kusuhara H, Ito K. Nakada T, et al. Drug Metab Pharmacokinet. 2019 Aug;34(4):233-238. doi: 10.1016/j.dmpk.2019.02.006. Epub 2019 Mar 2. Drug Metab Pharmacokinet. 2019. PMID: 31176593 Clinical Trial.
We tested 14 compounds (cimetidine, cobicistat, dolutegravir, dronedarone, DX-619, famotidine, INCB039110, nizatidine, ondansetron, pyrimethamine, rabeprazole, ranolazine, trimethoprim, and vandetanib), which were reported to cause reversible changes in SCr and/or CL(cre) …
We tested 14 compounds (cimetidine, cobicistat, dolutegravir, dronedarone, DX-619, famotidine, INCB039110, nizatidine, ondansetron, p …
Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.
Futagami S, Shimpuku M, Song JM, Kodaka Y, Yamawaki H, Nagoya H, Shindo T, Kawagoe T, Horie A, Gudis K, Iwakiri K, Sakamoto C. Futagami S, et al. Digestion. 2012;86(2):114-21. doi: 10.1159/000339111. Epub 2012 Jul 27. Digestion. 2012. PMID: 22846371 Clinical Trial.
In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with placebo (0/30; 0%). ...There were no significant differences in ghrelin levels between nizatidine treatment and placebo therapy. CONCL …
In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with p …
Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects.
Blum RA, Braverman AJ, Rice P, Johnson FK. Blum RA, et al. J Clin Pharmacol. 2003 Jan;43(1):74-83. doi: 10.1177/0091270002239709. J Clin Pharmacol. 2003. PMID: 12520631 Clinical Trial.
In multiple doses, the 24-hour AUC ratio for all comparisons of nizatidine CR 150 mg bid, nizatidine CR 300 mg daily, and nizatidine IR 150 mg bid was between 97% and 99%. Mean pH AUC values for nizatidine CR 150 mg bid and nizatidine IR 150 mg …
In multiple doses, the 24-hour AUC ratio for all comparisons of nizatidine CR 150 mg bid, nizatidine CR 300 mg daily, and n
Formulation, optimization, and evaluation of raft-forming formulations containing Nizatidine.
Darwish MKM, Abu El-Enin ASM, Mohammed KHA. Darwish MKM, et al. Drug Dev Ind Pharm. 2019 Apr;45(4):651-663. doi: 10.1080/03639045.2019.1569033. Epub 2019 Feb 7. Drug Dev Ind Pharm. 2019. PMID: 30638411 Clinical Trial.
OBJECTIVE: The main objective of this research is to formulate, optimize, and evaluate raft-forming chewable tablets of Nizatidine. Various raft-forming agents were used in preliminary screening. ...RESEARCH DESIGN AND METHODS: Raft forming chewable tablets containing N
OBJECTIVE: The main objective of this research is to formulate, optimize, and evaluate raft-forming chewable tablets of Nizatidine. V …
Effect of nizatidine on paracetamol and its metabolites in human plasma.
Itoh H, Nagano T, Takeyama M. Itoh H, et al. J Pharm Pharmacol. 2002 Jun;54(6):869-73. doi: 10.1211/0022357021779050. J Pharm Pharmacol. 2002. PMID: 12079004 Clinical Trial.
The effects of nizatidine could result from the inhibition of glucuronyltransferase. Thus, care is necessary when paracetamol and nizatidine are coadministered....
The effects of nizatidine could result from the inhibition of glucuronyltransferase. Thus, care is necessary when paracetamol and …
Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients.
Futagami S, Yamawaki H, Izumi N, Shimpuku M, Kodaka Y, Wakabayashi T, Nagoya H, Shindo T, Kawagoe T, Gudis K, Itoh T, Sakamoto C. Futagami S, et al. J Gastroenterol Hepatol. 2013 Aug;28(8):1314-20. doi: 10.1111/jgh.12236. J Gastroenterol Hepatol. 2013. PMID: 23611167 Clinical Trial.
Gastric motility was evaluated. Thirty-four FD patients were treated with nizatidine (300 mg/day) or placebo for 4 weeks in a crossover trial. The primary end point of this study was to determine whether nizatidine could improve clinical symptoms and sleep disorders …
Gastric motility was evaluated. Thirty-four FD patients were treated with nizatidine (300 mg/day) or placebo for 4 weeks in a crossov …
Developmental pharmacokinetics and pharmacodynamics of nizatidine.
Abdel-Rahman SM, Johnson FK, Connor JD, Staiano A, Dupont C, Tolia V, Winter H, Gauthier-Dubois G, Kearns GL. Abdel-Rahman SM, et al. J Pediatr Gastroenterol Nutr. 2004 Apr;38(4):442-51. doi: 10.1097/00005176-200404000-00015. J Pediatr Gastroenterol Nutr. 2004. PMID: 15085026 Clinical Trial.
Nizatidine formulation and dose were determined by age: infants received 2 or 4 mg/kg i.v., children 2.5 or 5 mg/kg in one of three oral liquid formulations, and adolescents and adults received a fixed 150-mg capsule. Nizatidine and N-desmethylnizatidine concentrati
Nizatidine formulation and dose were determined by age: infants received 2 or 4 mg/kg i.v., children 2.5 or 5 mg/kg in one of three o
Nizatidine and gastric emptying in functional dyspepsia.
Koskenpato J, Punkkinen JM, Kairemo K, Färkkilä M. Koskenpato J, et al. Dig Dis Sci. 2008 Feb;53(2):352-7. doi: 10.1007/s10620-007-9898-x. Epub 2007 Aug 9. Dig Dis Sci. 2008. PMID: 17682943 Clinical Trial.
The aim of this study was to evaluate the effect of nizatidine on gastric emptying in patients with functional dyspepsia. ...Nizatidine improved the symptom scores and seven of eight aspects of quality of life - but not significantly. ...
The aim of this study was to evaluate the effect of nizatidine on gastric emptying in patients with functional dyspepsia. ...Nizat
Intravenous nizatidine kinetics and acid suppression.
Callaghan JT, Bergstrom RF, Obermeyer BD, King EP, Offen WW. Callaghan JT, et al. Clin Pharmacol Ther. 1985 Feb;37(2):162-5. doi: 10.1038/clpt.1985.29. Clin Pharmacol Ther. 1985. PMID: 2857117 Clinical Trial.
Gastric acid suppression after nizatidine was contrasted with that after placebo and MSF. All doses of nizatidine reduced secretion; the 150- and 250-mg doses of nizatidine suppressed secretion for at least 2.5 hr. ...Again, all doses of nizatidine red …
Gastric acid suppression after nizatidine was contrasted with that after placebo and MSF. All doses of nizatidine reduced secr …
Effect of preoperative oral use of erythromycin and nizatidine on gastric pH and volume.
Memis D, Turan A, Karamanlioglu B, Guler T, Yurdakoc A, Pamukcu Z, Turan N. Memis D, et al. Anaesth Intensive Care. 2002 Aug;30(4):428-32. doi: 10.1177/0310057X0203000404. Anaesth Intensive Care. 2002. PMID: 12180579 Free article. Clinical Trial.
This randomized controlled trial examined the effects of preoperative oral erythromycin or nizatidine on gastric pH and volume. Sixty patients, ASA 1 and 2 status scheduled for elective surgery were studied. ...Patients in Group 1 (n=20) were given erythromycin 200 mg, in …
This randomized controlled trial examined the effects of preoperative oral erythromycin or nizatidine on gastric pH and volume. Sixty …
139 results